<DOC>
	<DOCNO>NCT02125864</DOCNO>
	<brief_summary>The purpose study examine plasma concentration vascular endothelial growth factor ( VEGF ) standard treatment one new growth factor inhibitor , aflibercept ( Eylea ) . Patients exudative age-related macular degeneration ( AMD ) treat today anti-growth factor ( anti-VEGF ) . Eylea appear long duration action eye powerful effect edema macula previously use growth factor inhibitor . This mean disease control few number injection eye investigator therefore reduce risk complication associate type treatment . It unclear plasma VEGF concentration treatment Eylea eye patient wet age-related macular degeneration .</brief_summary>
	<brief_title>Plasma Levels Vascular Endothelial Growth Factor Before After Intravitreal Injection Aflibercept</brief_title>
	<detailed_description>Macular edema secondary exudative age-related macular degeneration treat today primarily vascular endothelial growth factor inhibitor , anti-VEGF . There currently four anti-VEGF drug either approve off-label use ophthalmology . Pegaptanib ( Macugen , Pfizer ) , ranibizumab ( Lucentis , Novartis ) aflibercept ( Eylea , Bayer ) bevacizumab Avastin , Roche ) . They different molecule pharmacodynamics . VEGF play important role many physiological pathophysiological mechanism . Studies show even low-dose intravitreal treatment bevacizumab lead significant reduction VEGF plasma concentration month treatment patient exudative AMD . No significant systemic effect could detect intravitreal administration ranibizumab pegaptanib . The purpose study : - To determine intravitreal treatment Eylea affect VEGF plasma level patient exudative AMD - How long intravitreal injection VEGF plasma concentration affect ?</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Men woman exudative AMD Central Retinal Thickness ≥ 250 micron Best correct visual acuity 20/2520/320 Age ≥ 60 year Only one eye applicable recruitment Informed sign consent accord International Conference Harmonisation Good Clinical Practice place prior study . Bilateral disease Treatment intravitreal injection past three month Patients previously undergone vitrectomy Choroidal neovascular membrane secondary disease AMD Macula edema etiology wet AMD Intraocular pressure ≥ 30 mmHg mydriasis Active uveitis infectious condition study eye Patients use systemic anti inflammatory therapy ( steroid ) Patients use systemic antiVEGF treatment Blod pressure well regulate Dialysis need transplantation result renal failure Heart attack , stroke , transient ischemic attack last 6 month New York Heart Association class II , III , IV Known allergy aflibercept , fluorescein povidone iodine Unable follow study procedure</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>AMD</keyword>
	<keyword>VEGF</keyword>
	<keyword>Aflibercept</keyword>
</DOC>